Acquisition Opportunity Recent acquisition by Harmony Biosciences positions Epygenix's rare epilepsy portfolio under a larger CNS-focused pipeline, presenting a potential cross-sell and integration pathway for Harmony’s sales, distribution, and existing customer base to accelerate your rare epilepsy products.

Clinical Expansion Announcement of a second phase 3 study in Lennox-Gastaut syndrome indicates ongoing late-stage development and potential near-term demand for strategic partnerships, licensing, or co-development deals to leverage regulatory and market entry advantages.

Therapy Focus Targeting Dravet syndrome and other genetic epilepsies aligns with a high-need, specialized patient population and payer interest in precision medicine, suggesting opportunities for companion diagnostics, patient access programs, and payer-focused value dossiers.

Leadership Milestones New appointments of a Chief Medical Officer and Chief Financial Officer in 2022 reflect a maturation phase; engaging with the leadership team may yield discussions on clinical milestones, regulatory strategy, and financial planning relevant to partnering and investment discussions.

Financial Profile Small company revenue range with acquisition indication and a lean employee base signals readiness for partnership-driven growth, including potential for co-development funding, milestone-based deals, or strategic alliances with larger biotech or pharma players seeking rapid expansion in genetic epilepsy.